Drug Discovery Today

OCTOBER 27, 2022

On October 26?27, Vilnius will host the EFIB’2022 event which will bring the European life science sector together. In the field of life sciences, Lithuania is best known for the discovery of gene scissors by Prof. Virginijus Šikšnys. The country now hosts the EMBL Partnership Institute for Genome Editing Technologies at the Vilnius University Life Sciences Center aiming to advance gene editing technologies.

Science 214

Science International Research 214

Conversations in Drug Development Trends

OCTOBER 26, 2022

Bringing a psychedelic into a clinical trial setting is complex and requires a thorough operational approach to ensure the study’s success. Having worked in psychedelic research since the advent of industry-sponsored trials, Worldwide Clinical Trials has amassed the expertise needed to execute these studies successfully, recently sharing insights in a webinar titled “ Demystifying Complex Operations in Psychedelic Research ,” available on-demand now.

Trials 97

Trials Clinical Trials Licensing Licensing 97

Antidote

OCTOBER 26, 2022

At Antidote, our mission is to connect patients with clinical trials using a data-driven, technological approach — and one of the ways we do that is through our clinical trial search engine, Antidote Match ™.

Clinical Trials 94

Clinical Trials Engineering Trials 94

Drug Patent Watch

OCTOBER 24, 2022

This chart shows the pharmaceutical companies with the most patents in China. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in China? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 86

Pharmaceutical Companies Pharmaceuticals Drugs 86

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Treatment

Drug Discovery Today

OCTOBER 28, 2022

Investment in purpose-built facilities supports ongoing recruitment and growth in new product development activities First phase of new facility doubles overall space capacity, with view to expand further as later stages of building complete

Laboratories 113

Laboratories Production 113

Drug Channels

OCTOBER 25, 2022

Eeek! Time for my Halloween roundup of wicked Drug Channels’ tales. This month’s tricks and treats: Eerie! Mark Cuban tells ghost stories about PBMs. Shocking! Walgreens terrifies Wall Street with its 340B losses. Vampiric! Sink your fangs into Amgen’s fantastic new report on the biosimilar boom Wicked! Physicians think payers cast evil utilization management spells.

Biosimilars 83

Biosimilars Drugs Pharmacy 83

Drug Patent Watch

OCTOBER 28, 2022

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Spain. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Spain? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals 52

Drug Discovery Today

OCTOBER 27, 2022

On October 26?27, Vilnius will host the EFIB’2022 event which will bring the European life science sector together. In the field of life sciences, Lithuania is best known for the discovery of gene scissors by Prof. Virginijus Šikšnys. The country now hosts the EMBL Partnership Institute for Genome Editing Technologies at the Vilnius University Life Sciences Center aiming to advance gene editing technologies.

Science 100

Science International Research 100

Crown Bioscience

OCTOBER 28, 2022

Major advances in breast cancer treatment have significantly improved survival rates, but metastatic disease continues to be the leading cause of breast cancer-related deaths. Developing novel therapies for metastatic breast cancer requires preclinical breast cancer models that better-recapitulate important clinical features of the disease, including metastasis.

Therapies 52

Therapies Disease Treatment 52

Drug Channels

OCTOBER 28, 2022

Today’s guest post comes from Brooks Wildasin, Vice President of Product Management at CareMetx. Brooks introduces us to CareMetx’s specialty therapy warranty, a specialty patient outcome-based contract model. Download CareMetx’s 2022 Report: The Evolving Landscape of Digital Healthcare Hubs to learn more about digital hub services and CareMetx’s solutions that improve the patient journey.

Therapies 52

Therapies Production Drugs 52

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Drug Patent Watch

OCTOBER 28, 2022

Annual Drug Patent Expirations for OXBRYTA Oxbryta is a drug marketed by Global Blood Theraps and is included in two NDAs. There are nine patents protecting this drug. This drug…. The post New patent for Global Blood drug OXBRYTA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

The Strateos Blog: Drug Discovery

OCTOBER 27, 2022

The collaborative spirit in the life sciences sector is at an all-time high. The unprecedented level of cooperation across academia, biopharmaceutical companies, solution providers, startups, and government agencies in the face of one of the biggest public health challenges in recent history, has proven what’s possible when we work towards a common goal.

Science 52

Science Laboratories Compliance Engineering 52

Nvidia Developer: Drug Discovery

OCTOBER 24, 2022

A virtual event designed for healthcare developers and startups, this summit on November 10, 2022 offers a full day of technical talks to reach developers and. A virtual event designed for healthcare developers and startups, this summit on November 10, 2022 offers a full day of technical talks to reach developers and technical leaders in the EMEA region.

Science 52

Science Drugs 52

Antidote

OCTOBER 24, 2022

We often reference our patient database: 400,000+ patients who have raised their hands to take part in medical research and shared health data to help us determine eligibility. The beauty of the Antidote database is that it provides a real-word picture of true patient populations — their demographic information as well as health details such as conditions they have, medications they’re on, and condition-specific details.

Trials 52

Trials Research 52

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

Drug Patent Watch

OCTOBER 28, 2022

Annual Drug Patent Expirations for SUNOSI Sunosi is a drug marketed by Axsome Malta and is included in one NDA. It is available from one supplier. There are nine patents…. The post New patent for Axsome Malta drug SUNOSI appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

The Premier Consulting Blog

OCTOBER 26, 2022

During the development cycle of a regulated therapeutic, the transfer of the manufacturing process is inevitable. The process will be transferred from the development lab to a pilot or small-scale manufacturing facility and, if the program is successful, to a facility for commercial manufacturing. With each transfer, important information needs to be readily available to the receiving party to ensure the required utilities, facilities, and equipment are available for the successful implementatio

Production 40

Production Assay Development Clinical Supply Engineering 40

Translation

OCTOBER 26, 2022

Leading packaging providers, an innovative American biotech company, and a biomaterials research company join Halo to bring new innovations to the world and move science forward. We are delighted to welcome four new customers to Halo’s platform: Amcor Limited, a global producer of sustainable packaging; Altium Packaging, a leading packaging solutions provider; Ginkgo Bioworks, an American biotechnology company specializing in genetic engineering; and one.five, a biomaterials research company.

Packaging 52

Packaging Production Engineering Pharmaceuticals 52

Drug & Device Law

OCTOBER 26, 2022

More plaintiffs, more money. And we don’t mean a mere linear increase. If, as Hegel said, quantitative differences ultimately become qualitative differences, in litigation that happens when going from one plaintiff to two, and certainly to several or many. When a jury sees multiple people bringing claims against a defendant, they think something’s up, where there’s smoke there’s fire, and the defendant must have done something wrong.

Production 59

Production Disease Trials 59

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

Drug Patent Watch

OCTOBER 28, 2022

Annual Drug Patent Expirations for IBSRELA Ibsrela is a drug marketed by Ardelyx Inc and is included in one NDA. There are four patents protecting this drug. This drug has…. The post New patent for Ardelyx Inc drug IBSRELA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

The Premier Consulting Blog

OCTOBER 24, 2022

The Marketing Authorization (MA) holder for a treatment for onychomycosis, having previously secured regulatory approval in several markets, sought to introduce the product to the European market. Completion of the Marketing Authorization Application (MAA) required utilization of the Active Substance Master File (ASMF) procedure, which is designed to facilitate evaluation of the suitability of the use of the active substance in the medicinal product.

Production 40

Production Marketing Treatment Disease 40

Drug Patent Watch

OCTOBER 28, 2022

Annual Drug Patent Expirations for RYDAPT Rydapt is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are three patents protecting…. The post New patent expiration for Novartis drug RYDAPT appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

OCTOBER 28, 2022

Annual Drug Patent Expirations for ZONISADE Zonisade is a drug marketed by Azurity and is included in one NDA. It is available from one supplier. The generic ingredient in ZONISADE…. The post New patent for Azurity drug ZONISADE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

OCTOBER 28, 2022

Annual Drug Patent Expirations for EMERPHED Emerphed is a drug marketed by Nexus Pharms and is included in one NDA. It is available from one supplier. There are two patents…. The post New patent for Nexus Pharms drug EMERPHED appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

OCTOBER 27, 2022

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Romania. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Romania? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals 52

Drug Patent Watch

OCTOBER 26, 2022

This chart shows the drugs with the most patents in Chile. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Chile? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceuticals 52

Pharmaceuticals Drugs 52

Drug Patent Watch

OCTOBER 26, 2022

[![eltrombopag structure]([link] Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting this compound. There are four…. The post New tentative approval for Teva Pharms drug eltrombopag appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

OCTOBER 26, 2022

[![saxagliptin structure]([link] Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents protecting this compound. There are…. The post New tentative approval for Amneal Pharms drug saxagliptin appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

OCTOBER 26, 2022

Annual Drug Patent Expirations for ANJESO Anjeso is a drug marketed by Baudax and is included in one NDA. There are seven patents protecting this drug. Drug patent litigation for…. The post New patent for Baudax drug ANJESO appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

OCTOBER 25, 2022

This chart shows the pharmaceutical companies with the most patents in Spain. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Spain? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Drugs 52

Drug Patent Watch

OCTOBER 24, 2022

Annual Drug Patent Expirations for TRI-LUMA Tri-luma is a drug marketed by Galderma Labs Lp and is included in one NDA. It is available from one supplier. There are four…. The post New patent expiration for Galderma Labs drug TRI-LUMA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

OCTOBER 24, 2022

Annual Drug Patent Expirations for GRALISE Gralise is a drug marketed by Almatica and is included in one NDA. It is available from two suppliers. There are five patents protecting…. The post New patent expiration for Almatica drug GRALISE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

OCTOBER 28, 2022

[![saxagliptin structure]([link] Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents protecting this compound. There are…. The post New tentative approval for Amneal Pharms drug saxagliptin appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40

Drugs Marketing 40

Drug Patent Watch

OCTOBER 28, 2022

[![eltrombopag structure]([link] Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting this compound. There are four…. The post New tentative approval for Teva Pharms drug eltrombopag appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40

Drugs Marketing 40